In an acknowledgement that post-election jitters are a significant concern, senior officials at the US FDA are advising members of the rank-and-file to concentrate on their work instead of thinking about potential changes that could be made at the agency by the incoming Trump administration.
Woodcock Tries To Calm US FDA Staff Fears About Trump
CDER Director's' video advises focusing on the work and "keeping our heads down."
More from US FDA
More from Agency Leadership
• By
Pink Sheet reporter and editors discuss how the massive layoffs will reshape the FDA and its impact on the drug and biologics industries.
• By
Former Acting FDA Commissioner Sara Brenner is said to have asked Tracy Beth Høeg, new special assistant to the commissioner, to help reexamine the application. Høeg’s position at the agency is raising concerns about the FDA's ongoing approach to vaccine regulation.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.